What is LIGAND PHARMS GLUCAGON's earnings per share (EPS)?

LIGAND PHARMS GLUCAGON (LGNXZ) reported diluted earnings per share of $6.13 for fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

LIGAND PHARMS GLUCAGON (LGNXZ) Financials

LGNXZ

Trailing 12 months to June 30, 2026

Revenue $290.5M +54.9% YoY

Net Income $197.2M n/m YoY

EPS (Diluted) $9.41 n/m YoY

Free Cash Flow $131.4M +145.1% YoY

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 7, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 7, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the LGNXZ SEC filings page.

LIGAND PHARMS GLUCAGON (LGNXZ) reported $290.5M in revenue over the twelve months to Jun 30, 2026, up 54.9% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI LGNXZ FY2025 2026-10-03

Reported profit rebounded sharply, but FY2025 cash generation stayed modest and expansion relied heavily on financing rather than operations.

Earnings quality diverged from reported profitability: FY2025 net income reached $124M versus operating income of $41M, while operating cash flow was only $49M. The resulting gap means the income statement benefited from items beyond core operating earnings and did not translate proportionately into cash.

Operating performance recovered as the operating margin moved from -13.5% in FY2024 to 15.3% in FY2025. Revenue reached $268M while R&D rose to $81M, showing that the rebound came alongside substantial reinvestment rather than simple cost reduction.

Capital deployment accelerated: total assets expanded to $1.6B while investing cash flow was -$377M, indicating a major expansion in the balance sheet. Financing cash flow of $428M alongside operating cash flow of $49M shows that this deployment was funded largely outside annual operating cash generation.

Financial Health Signals

Financial health score not available

LIGAND PHARMS GLUCAGON does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

4/7

LIGAND PHARMS GLUCAGON passes 4 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 3 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, the one computable operating efficiency signal (asset turnover improving) does not pass.

Earnings Quality Low Quality

0.40x

For every $1 of reported earnings, LIGAND PHARMS GLUCAGON generates $0.40 in operating cash flow ($49.4M OCF vs $124.5M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage Safe

8.70x

LIGAND PHARMS GLUCAGON earns $8.70 in operating income for every $1 of interest expense ($41.0M vs $4.7M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$63.7M

YoY+33.7%

QoQ+23.1%

5Y CAGR-4.2%

10Y CAGR+12.6%

LIGAND PHARMS GLUCAGON generated $63.7M in revenue in Q2 2026. This represents an increase of 33.7% from the same quarter a year earlier. Against the prior quarter it is up 23.1%.

EBITDA

$16.8M

YoY-0.9%

QoQ-34.3%

LIGAND PHARMS GLUCAGON's EBITDA was $16.8M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 0.9% from the same quarter a year earlier. Against the prior quarter it is down 34.3%.

Net Income

$48.5M

YoY+900.8%

QoQn/m

5Y CAGR+9.6%

10Y CAGRn/m

LIGAND PHARMS GLUCAGON reported $48.5M in net income in Q2 2026. This represents an increase of 900.8% from the same quarter a year earlier. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

EPS (Diluted)

$2.22

YoY+825.0%

QoQn/m

LIGAND PHARMS GLUCAGON earned $2.22 per diluted share (EPS) in Q2 2026. This represents an increase of 825.0% from the same quarter a year earlier. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Cash & Balance Sheet

Free Cash Flow

$24.0M

YoY+53.9%

QoQ-50.5%

5Y CAGR+4.8%

LIGAND PHARMS GLUCAGON generated $24.0M in free cash flow in Q2 2026, representing cash available after capex. This represents an increase of 53.9% from the same quarter a year earlier. Against the prior quarter it is down 50.5%.

Cash & Debt

$1.0B

YoY+1387.7%

QoQ+774.8%

5Y CAGR+115.1%

10Y CAGR+32.3%

LIGAND PHARMS GLUCAGON held $1.0B in cash against $1.1B in long-term debt as of Q2 2026.

Shares Outstanding

20M

YoY+1.7%

QoQ-0.5%

LIGAND PHARMS GLUCAGON had 20M shares outstanding in Q2 2026. This represents an increase of 1.7% from the same quarter a year earlier. Against the prior quarter it is down 0.5%.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Operating Margin

13.5%

YoY-4.2pp

QoQ-20.1pp

LIGAND PHARMS GLUCAGON's operating margin was 13.5% in Q2 2026, reflecting core business profitability. This is down 4.2 percentage points from the same quarter a year earlier. Against the prior quarter it is down 20.1 percentage points.

Net Margin

76.2%

YoY+66.0pp

QoQ+102.0pp

5Y change+37.2pp

10Y change+107.8pp

LIGAND PHARMS GLUCAGON's net profit margin was 76.2% in Q2 2026, showing the share of revenue converted to profit. This is up 66.0 percentage points from the same quarter a year earlier. Against the prior quarter it is up 102.0 percentage points.

Return on Equity

5.0%

YoY+4.4pp

QoQ+6.3pp

5Y change+1.1pp

10Y change+6.9pp

LIGAND PHARMS GLUCAGON's quarterly ROE was 5.0% in Q2 2026: one quarter's net income over shareholder equity, not annualized. This is up 4.4 percentage points from the same quarter a year earlier. Against the prior quarter it is up 6.3 percentage points.

Gross Margin

Not reported for Q2 2026.

Capital Allocation

R&D Spending

$14.7M

YoY+123.4%

QoQ+582.9%

5Y CAGR+14.4%

LIGAND PHARMS GLUCAGON invested $14.7M in research and development in Q2 2026. This represents an increase of 123.4% from the same quarter a year earlier. Against the prior quarter it is up 582.9%.

Capital Expenditures

$26K

YoY-87.9%

QoQ-88.6%

5Y CAGR-54.9%

LIGAND PHARMS GLUCAGON invested $26K in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 87.9% from the same quarter a year earlier. Against the prior quarter it is down 88.6%.

Share Buybacks

Not reported for Q2 2026.

LGNXZ Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

LGNXZ quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	$290.5M	$268.1M+60.4%	$167.1M+27.3%	$131.3M-33.1%	$196.2M-18.8%	$241.5M+47.7%	$163.6M+36.0%	$120.3M-52.2%	$251.5M+78.2%	$141.1M+29.5%	$109.0M+51.5%	$71.9M+11.4%	$64.5M+31.8%	$49.0M+56.0%	$31.4M+4.5%	$30.0M
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$6.3M+18.1%	$5.4M-3.7%	$5.6M-4.1%	$5.8M-36.4%	$9.1M+59.4%	$5.7M+59.2%	$3.6M-26.6%	$4.9M
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$245.1M+80.6%	$135.7M+31.3%	$103.4M+56.4%	$66.1M+19.3%	$55.4M+28.1%	$43.2M+55.6%	$27.8M+10.6%	$25.1M
R&D Expenses	$41.3M	$81.2M+278.9%	$21.4M-12.7%	$24.5M-32.0%	$36.1M+12.4%	$32.1M-20.7%	$40.5M-27.6%	$55.9M+100.7%	$27.9M+3.6%	$26.9M+26.7%	$21.2M+92.8%	$11.0M+12.9%	$9.7M+5.1%	$9.3M-14.1%	$10.8M+4.8%	$10.3M
SG&A Expenses	$103.4M	$92.4M+17.5%	$78.7M+49.0%	$52.8M-24.7%	$70.1M+49.7%	$46.8M-22.0%	$60.0M+43.3%	$41.9M+11.0%	$37.7M+31.7%	$28.7M+3.6%	$27.7M+8.9%	$25.4M+12.5%	$22.6M+25.5%	$18.0M+14.0%	$15.8M+8.2%	$14.6M
Operating Income	$94.7M	$41.0Mn/m	-$22.6M-289.3%	$11.9M+293.2%	$3.0M-97.1%	$103.9M+176.9%	$37.5M-95.4%	$807.1M+392.9%	$163.7M+140.5%	$68.1M+55.1%	$43.9M+60.6%	$27.3M+39.2%	$19.6M+31.3%	$14.9M+7642.5%	$193Kn/m	-$878K
EBITDA	N/A	$74.8M+491.9%	$12.6M-73.9%	$48.5M-11.2%	$54.6M-64.8%	$154.9M+145.2%	$63.2M-92.3%	$825.4M+367.6%	$176.5M+123.3%	$79.0M+43.2%	$55.2M+84.2%	$30.0M+34.4%	$22.3M+26.6%	$17.6M+502.9%	$2.9M+52.7%	$1.9M
Interest Expense	$6.2M	$4.7M+55.3%	$3.0M+363.0%	$656K-63.5%	$1.8M-90.8%	$19.6M-28.4%	$27.4M-23.3%	$35.7M-26.0%	$48.3M+258.7%	$13.5M+4.8%	$12.8M	N/A	$4.9M+134.0%	$2.1M-29.0%	$2.9M+16.6%	$2.5M
Income Tax	$40.7M	$34.5M+426.8%	$6.5M-33.4%	$9.8M-76.1%	$41.2Mn/m	-$4.1Mn/m	-$5.3M-103.2%	$167.3M+457.6%	$30.0M-32.8%	$44.7M+332.6%	$10.3Mn/m	-$192.1M-46957.3%	$410K+9.6%	$374Kn/m	-$1.2Mn/m	-$13.3M
Net Income	$197.2M	$124.5Mn/m	-$4.0M-107.7%	$52.2Mn/m	-$33.4M-158.4%	$57.1Mn/m	-$3.0M-100.5%	$629.3M+339.1%	$143.3M+1041.5%	$12.6Mn/m	-$1.6M-100.7%	$229.8M+1811.4%	$12.0M+5.3%	$11.4Mn/m	-$527K-105.4%	$9.7M
EPS (Basic)	N/A	$6.44n/m	-$0.22-107.3%	$3.02n/m	-$1.98-157.6%	$3.44n/m	-$0.18-100.5%	$33.13+389.4%	$6.77+1028.3%	$0.60n/m	-$0.08-100.7%	$11.61+1867.8%	$0.59+5.4%	$0.56n/m	-$0.03-106.1%	$0.49
EPS (Diluted)	$9.41	$6.13n/m	-$0.22-107.5%	$2.94n/m	-$1.98-159.8%	$3.31n/m	-$0.18-100.6%	$31.85+434.4%	$5.96+1024.5%	$0.53n/m	-$0.08-100.7%	$10.83+1833.9%	$0.56+1.8%	$0.55n/m	-$0.03-106.1%	$0.49
Diluted Shares (Avg)	N/A	20M+11.0%	18M+3.0%	18M+5.3%	17M-2.2%	17M+2.5%	17M-14.8%	20M-17.9%	24M+2.5%	23M+12.7%	21M-1.9%	21M-1.0%	21M+3.3%	21M+4.5%	20M+0.7%	20M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$63.7M+33.7%	$51.7M+14.1%	$59.7M+39.4%	$115.5M+122.8%	$47.6M+14.7%	$45.3M+46.3%	$42.8M+52.4%	$51.8M+57.6%
R&D Expenses	$14.7M+123.4%	$2.1M-95.7%	$3.5M-20.7%	$21.0M+270.4%	$6.6M+22.7%	$50.1M+738.8%	$4.4M-19.4%	$5.7M+2.6%
SG&A Expenses	$29.1M+44.4%	$20.8M+10.8%	$25.0M-2.3%	$28.4M+16.2%	$20.2M+14.5%	$18.8M+71.7%	$25.6M+60.1%	$24.5M+67.0%
Operating Income	$8.6M+1.7%	$17.4Mn/m	$13.8Mn/m	$54.9M+1647.7%	$8.4Mn/m	-$36.2M-1312.0%	-$9.6Mn/m	$3.1M+2.1%
EBITDA	$16.8M-0.9%	$25.6Mn/m	$22.1Mn/m	$63.2M+420.7%	$17.0Mn/m	-$27.4M-333.5%	-$1.0M-118.2%	$12.1M+3.8%
Interest Expense	$1.7M+51.6%	$1.7M+101.5%	$1.8M+101.2%	$910K+22.8%	$1.2M-9.1%	$867K+514.9%	$887K+577.1%	$741K+74000.0%
Income Tax	$15.8M+147.7%	-$10.9Mn/m	$12.0Mn/m	$23.9M+2764.8%	$6.4Mn/m	-$7.7M-128.3%	-$8.1Mn/m	$833Kn/m
Net Income	$48.5M+900.8%	-$13.3Mn/m	$44.8Mn/m	$117.3Mn/m	$4.8Mn/m	-$42.5M-149.3%	-$31.1M-270.9%	-$7.2Mn/m
EPS (Basic)	$2.42+868.0%	-$0.67n/m	$2.33n/m	$5.99n/m	$0.25n/m	-$2.21-145.5%	-$1.72-263.8%	-$0.39n/m
EPS (Diluted)	$2.22+825.0%	-$0.67n/m	$2.18n/m	$5.68n/m	$0.24n/m	-$2.21-146.5%	-$1.68-263.1%	-$0.39n/m
Diluted Shares (Avg)	22M+9.6%	20M+3.6%	N/A	21M+12.0%	20M+10.5%	19M+5.9%	N/A	18M+6.0%

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.

LGNXZ Balance Sheet

LGNXZ quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$1.6B+65.7%	$941.8M+19.6%	$787.2M+3.2%	$762.7M-41.2%	$1.3B-4.7%	$1.4B-8.9%	$1.5B+18.6%	$1.3B+87.9%	$671.0M+11.5%	$601.6M+19.6%	$503.1M+95.0%	$258.0M+146.4%	$104.7M+0.4%	$104.3M-13.5%	$120.6M
Current Assets	$832.3M+151.0%	$331.6M+39.6%	$237.4M-9.9%	$263.6M-43.3%	$464.8M-7.2%	$500.6M-55.5%	$1.1B+29.1%	$870.5M+267.3%	$237.0M+45.4%	$163.1M-24.1%	$214.7M+16.0%	$185.2M+644.2%	$24.9M+4.4%	$23.8M-26.1%	$32.2M
Cash & Equivalents	$174.9M+141.9%	$72.3M+215.0%	$23.0M-49.0%	$45.0M+130.5%	$19.5M-59.0%	$47.6M-33.4%	$71.5M-38.9%	$117.2M+468.2%	$20.6M+10.0%	$18.8M-80.8%	$97.4M-39.2%	$160.2M+1276.4%	$11.6M-6.0%	$12.4M+75.8%	$7.0M
Short-Term Investments	$558.6M+203.8%	$183.9M+24.8%	$147.4M-11.7%	$166.9M-48.1%	$321.6M-11.5%	$363.6M-63.6%	$998.3M+66.1%	$601.2M+232.1%	$181.0M+48.0%	$122.3M+19.0%	$102.8M+1341.1%	$7.1M+64.4%	$4.3Mn/m	$0-100.0%	$10.0M
Inventory	$9.1M-35.3%	$14.1M-41.1%	$24.0M+80.3%	$13.3M-51.4%	$27.3M+3.2%	$26.5M+263.0%	$7.3M+2.4%	$7.1M+62.9%	$4.4M+127.4%	$1.9M+17.8%	$1.6M+507.1%	$269K-80.7%	$1.4M-18.0%	$1.7M+30.4%	$1.3M
Accounts Receivable	$59.6M+55.3%	$38.4M+16.6%	$32.9M+8.2%	$30.4M-64.4%	$85.5M+50.3%	$56.8M+87.1%	$30.4M-45.6%	$55.9M	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Long-Term Investments	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0
Goodwill	$101.5M-3.5%	$105.3M+1.8%	$103.4Mn/m	$0-100.0%	$105.7M-44.3%	$189.7M+99.2%	$95.2M+9.9%	$86.6M+0.8%	$86.0M+19.0%	$72.2M+490.0%	$12.2M0.0%	$12.2M0.0%	$12.2M0.0%	$12.2M0.0%	$12.2M
Total Liabilities	$543.4M+388.1%	$111.3M+29.0%	$86.3M-47.8%	$165.2M-65.3%	$476.4M-27.0%	$652.8M-10.3%	$727.7M+4.0%	$699.9M+177.3%	$252.4M+9.4%	$230.7M+2.0%	$226.2M-3.2%	$233.6M+324.0%	$55.1M-29.2%	$77.8M-25.3%	$104.1M
Current Liabilities	$37.4M+0.9%	$37.1M+121.1%	$16.8M-83.0%	$98.8M+137.2%	$41.7M-58.4%	$100.1M+488.8%	$17.0M-79.3%	$82.2M-65.6%	$238.9M+5.2%	$227.1M+1.9%	$222.8M+878.2%	$22.8M-21.3%	$28.9M-18.3%	$35.4M-18.8%	$43.6M
Non-Current Liabilities	$506.0M+581.7%	$74.2M+6.8%	$69.5M+4.7%	$66.4M-84.7%	$434.8M-21.3%	$552.6M-22.2%	$710.7M+15.1%	$617.6M+4473.1%	$13.5M+274.9%	$3.6M+8.2%	$3.3M-98.4%	$210.8M+705.9%	$26.2M-38.2%	$42.3M-29.9%	$60.4M
Long-Term Debt	N/A	N/A	N/A	$0-100.0%	$320.7M-27.5%	$442.3M-30.8%	$639.0M+4.8%	$609.9Mn/m	$0	N/A	$0-100.0%	$195.9M	N/A	$27.5M	N/A
Total Equity	$1.0B+22.5%	$830.4M+18.5%	$700.9M+17.3%	$597.5M-27.2%	$821.2M+15.7%	$709.5M-7.5%	$767.2M+36.8%	$560.9M+40.3%	$399.8M+17.1%	$341.3M+43.8%	$237.3M+801.6%	$26.3M-47.0%	$49.6M+87.3%	$26.5M+223.6%	$8.2M
Retained Earnings	$608.1M+21.9%	$499.0M-0.8%	$503.0M+11.6%	$450.9M+0.4%	$449.1M+14.6%	$392.0M-2.0%	$400.1Mn/m	-$229.2Mn/m	-$400.9Mn/m	-$431.1Mn/m	-$429.5Mn/m	-$659.3Mn/m	-$671.3Mn/m	-$682.8Mn/m	-$682.2M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$2.2B+130.4%	$1.5B+69.2%	$1.6B+65.7%	$1.5B+54.7%	$948.6M+9.5%	$905.4M-0.9%	$941.8M+19.6%	$954.9M+24.1%
Current Assets	$1.5B+312.8%	$865.4M+179.8%	$832.3M+151.0%	$753.9M+143.7%	$352.9M+13.0%	$309.3M-16.2%	$331.6M+39.6%	$309.4M+21.8%
Cash & Equivalents	$1.0B+1387.7%	$115.1M+139.8%	$174.9M+141.9%	$139.4M+119.1%	$67.7M+273.1%	$48.0M-4.2%	$72.3M+215.0%	$63.6M+230.1%
Short-Term Investments	$351.1M+97.9%	$664.3M+312.9%	$558.6M+203.8%	$525.1M+236.6%	$177.4M-15.1%	$160.9M-38.2%	$183.9M+24.8%	$156.0M-8.9%
Inventory	$10.3M-33.7%	$13.3M-9.2%	$9.1M-35.3%	$11.9M-28.9%	$15.5M-17.0%	$14.6M-31.5%	$14.1M-41.1%	$16.7M-34.1%
Accounts Receivable	$67.0M+62.3%	$53.4M+38.7%	$59.6M+55.3%	$57.6M+67.7%	$41.3M+10.2%	$38.5M+35.4%	$38.4M+16.6%	$34.3M-4.7%
Long-Term Investments	N/A	$0n/m	N/A	$0n/m	N/A	$0n/m	N/A	$0
Goodwill	$101.5M0.0%	$101.5M0.0%	$101.5M-3.5%	$101.5M-3.5%	$101.5M-3.5%	$101.5M-3.5%	$105.3M+1.8%	$105.3M+1.4%
Total Liabilities	$1.2B+914.7%	$534.8M+386.6%	$543.4M+388.1%	$526.6M+363.2%	$120.1M+31.7%	$109.9M+2.4%	$111.3M+29.0%	$113.7M+12.2%
Current Liabilities	$46.7M-27.8%	$40.7M-30.7%	$37.4M+0.9%	$30.5M+23.3%	$64.7M+248.7%	$58.7M+229.3%	$37.1M+121.1%	$24.8M+57.5%
Non-Current Liabilities	$1.2B+2017.1%	$494.1M+864.7%	$506.0M+581.7%	$496.1M+457.9%	$55.3M-23.8%	$51.2M-42.8%	$74.2M+6.8%	$88.9M+3.9%
Long-Term Debt	$1.1B	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$967.5M+16.9%	$997.3M+25.4%	$1.0B+22.5%	$950.2M+13.0%	$827.3M+6.7%	$795.6M-1.4%	$830.4M+18.5%	$841.2M+25.9%
Retained Earnings	$583.3M+26.4%	$594.7M+30.3%	$608.1M+21.9%	$578.2M+9.1%	$461.4M-14.1%	$456.5M-22.5%	$499.0M-0.8%	$530.1M+9.3%

LGNXZ Cash Flow Statement

LGNXZ quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	$131.7M	$49.4M-49.1%	$97.0M+95.8%	$49.6M-64.0%	$137.8M+74.9%	$78.8M+44.4%	$54.6Mn/m	-$29.3M-115.1%	$194.1M+119.1%	$88.6M+45.8%	$60.7M+45.5%	$41.7M+102.9%	$20.6M-0.6%	$20.7M+12750.9%	$161Kn/m	-$1.2M
Depreciation & Amortization	N/A	$33.8M-4.2%	$35.2M-3.5%	$36.5M-29.1%	$51.5M+0.9%	$51.1M+98.8%	$25.7M+39.9%	$18.4M+43.6%	$12.8M+16.7%	$11.0M-3.0%	$11.3M+329.8%	$2.6M-1.1%	$2.7M-0.2%	$2.7M-2.3%	$2.7M-2.3%	$2.8M
Stock-Based Compensation	N/A	$46.8M+14.0%	$41.1M+59.6%	$25.7M-57.3%	$60.3M+55.4%	$38.8M+26.2%	$30.7M+25.3%	$24.5M+17.6%	$20.8M-16.3%	$24.9M+31.9%	$18.9M+51.7%	$12.5M+10.5%	$11.3M+98.9%	$5.7M+39.3%	$4.1M+21.4%	$3.4M
Capital Expenditures	$278K	$452K-75.2%	$1.8M-48.3%	$3.5M-80.4%	$17.9M+104.6%	$8.8M+96.5%	$4.5M+74.6%	$2.6M+187.8%	$887K-58.9%	$2.2M+16.5%	$1.9M+1889.2%	$93K+1450.0%	$6K-98.4%	$377K-36.6%	$595K+662.8%	$78K
Free Cash Flow	$131.4M	$48.9M-48.6%	$95.2M+106.8%	$46.1M-61.6%	$119.9M+71.2%	$70.0M+39.7%	$50.1Mn/m	-$31.9M-116.5%	$193.2M+123.5%	$86.4M+46.8%	$58.9M+41.4%	$41.6M+102.5%	$20.6M+1.2%	$20.3Mn/m	-$434Kn/m	-$1.3M
Investing Cash Flow	-$144.8M	-$377.3Mn/m	-$143.7Mn/m	-$11.7M-107.1%	$163.6M+436.1%	$30.5M-86.8%	$231.6M-50.4%	$466.9Mn/m	-$423.3Mn/m	-$79.2Mn/m	-$134.4Mn/m	-$112.9Mn/m	-$2.0Mn/m	-$5.0M-493.8%	$1.3Mn/m	-$25.1M
Financing Cash Flow	$950.3M	$428.2M+340.8%	$97.1Mn/m	-$59.9Mn/m	-$276.0Mn/m	-$137.8Mn/m	-$310.5Mn/m	-$485.2M-247.7%	$328.6Mn/m	-$7.5Mn/m	-$5.0M-159.7%	$8.4M-93.6%	$130.0Mn/m	-$16.5M-520.3%	$3.9M-86.9%	$30.0M
Share Buybacks	N/A	$15.0Mn/m	$0n/m	$0n/m	$0n/m	$0-100.0%	$78.0M-82.8%	$453.0M+268.7%	$122.9M+6149.6%	$2.0M-49.6%	$3.9M+697.8%	$489K-99.3%	$68.0Mn/m	$0n/m	$0-100.0%	$55K

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	$24.0M+52.0%	$48.7Mn/m	$45.9M+61.3%	$13.1M-64.2%	$15.8M+18.7%	-$25.4M-235.8%	$28.5M+253.0%	$36.5M+377.8%
Depreciation & Amortization	$8.2M-3.6%	$8.2M-6.3%	$8.2M-4.8%	$8.3M-8.1%	$8.5M-3.7%	$8.8M+0.1%	$8.6M-3.2%	$9.0M+4.4%
Stock-Based Compensation	N/A	$10.6M+35.2%	N/A	N/A	N/A	$7.8M+6.8%	N/A	N/A
Capital Expenditures	$26K-87.9%	$228K+6.5%	$9K-98.7%	$15K-97.5%	$214K-47.5%	$214K+103.8%	$712K+70.7%	$596K+22.4%
Free Cash Flow	$24.0M+53.9%	$48.5Mn/m	$45.9M+65.4%	$13.1M-63.6%	$15.6M+20.8%	-$25.7M-237.8%	$27.8M+263.0%	$35.9M+401.9%
Investing Cash Flow	$321.1Mn/m	-$94.3M-2027.8%	-$18.1Mn/m	-$353.4Mn/m	-$10.7Mn/m	$4.9Mn/m	-$38.6Mn/m	-$46.5Mn/m
Financing Cash Flow	$546.4M+3544.1%	-$14.1Mn/m	$8.3M-59.1%	$409.6M+643.7%	$15.0M+58.0%	-$4.7M-139.0%	$20.4M+283.6%	$55.1M+1584.4%
Share Buybacks	N/A	N/A	$0n/m	$15.0M	N/A	N/A	$0	N/A

Not reported in any period shown, so not listed: Dividends Paid.

LGNXZ Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

LGNXZ quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	97.5%+1.3pp	96.2%+1.3pp	94.9%+3.0pp	91.9%+6.1pp	85.8%-2.5pp	88.3%-0.2pp	88.5%+4.9pp	83.7%
Operating Margin	15.3%+28.8pp	-13.5%-22.6pp	9.1%+7.5pp	1.6%-41.4pp	43.0%+20.1pp	22.9%	671.0%	65.1%+16.9pp	48.3%+8.0pp	40.3%+2.3pp	38.0%+7.6pp	30.4%-0.1pp	30.5%+29.9pp	0.6%+3.5pp	-2.9%
Net Margin	46.4%+48.8pp	-2.4%-42.1pp	39.7%+56.7pp	-17.0%-40.7pp	23.7%+25.5pp	-1.8%	523.2%	57.0%+48.1pp	8.9%+10.4pp	-1.5%	319.6%	18.6%-4.7pp	23.3%+25.0pp	-1.7%-34.0pp	32.3%
Return on Equity	12.2%+12.7pp	-0.5%-7.9pp	7.4%+13.0pp	-5.6%-12.5pp	7.0%+7.4pp	-0.4%-82.4pp	82.0%+56.5pp	25.6%+22.4pp	3.1%+3.6pp	-0.5%-97.3pp	96.9%+51.2pp	45.7%+22.7pp	23.0%+25.0pp	-2.0%-120.7pp	118.7%
Return on Assets	8.0%+8.4pp	-0.4%-7.1pp	6.6%+11.0pp	-4.4%-8.8pp	4.4%+4.6pp	-0.2%-42.3pp	42.1%+30.7pp	11.4%+9.5pp	1.9%+2.1pp	-0.3%-46.0pp	45.7%+41.0pp	4.7%-6.3pp	10.9%+11.4pp	-0.5%-8.6pp	8.1%
Current Ratio	22.23+13.3x	8.93-5.2x	14.15+11.5x	2.67-8.5x	11.15+6.2x	5.00-61.1x	66.09+55.5x	10.58+9.6x	0.99+0.3x	0.72-0.2x	0.96-7.2x	8.13+7.3x	0.86+0.2x	0.67-0.1x	0.74
Debt-to-Equity	N/A	N/A	N/A	0.00-0.4x	0.39-0.2x	0.62-0.2x	0.83-0.3x	1.09+1.1x	0.00	N/A	0.00-7.4x	7.44	N/A	1.04	N/A
Liabilities-to-Equity	0.53+0.4x	0.130.0x	0.12-0.2x	0.28-0.3x	0.58-0.3x	0.920.0x	0.95-0.3x	1.25+0.6x	0.630.0x	0.68-0.3x	0.95-7.9x	8.88+7.8x	1.11-1.8x	2.94-9.8x	12.71
Asset Turnover	0.170.0x	0.180.0x	0.17-0.1x	0.26+0.1x	0.19+0.1x	0.120.0x	0.08-0.1x	0.200.0x	0.210.0x	0.180.0x	0.14-0.1x	0.25-0.2x	0.47+0.2x	0.30+0.1x	0.25
FCF Margin	18.2%-38.7pp	57.0%+21.9pp	35.1%-26.0pp	61.1%+32.1pp	29.0%-1.7pp	30.6%+57.2pp	-26.5%-103.3pp	76.8%+15.6pp	61.2%+7.2pp	54.0%-3.9pp	57.9%+26.0pp	31.9%-9.6pp	41.5%+42.9pp	-1.4%+2.8pp	-4.2%

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Margin	13.5%-4.2pp	33.6%+113.5pp	23.2%+45.7pp	47.6%+41.5pp	17.7%+63.7pp	-79.9%-89.5pp	-22.5%-10.6pp	6.1%-3.3pp
Net Margin	76.2%+66.0pp	-25.8%+67.8pp	75.1%+147.7pp	101.6%	10.2%	-93.6%	-72.6%-137.3pp	-13.8%+17.4pp
Return on Equity	5.0%+4.4pp	-1.3%+4.0pp	4.4%+8.1pp	12.3%+13.2pp	0.6%+7.3pp	-5.3%-16.0pp	-3.7%-6.3pp	-0.9%+0.7pp
Return on Assets	2.2%+1.7pp	-0.9%+3.8pp	2.9%+6.2pp	7.9%+8.7pp	0.5%+6.5pp	-4.7%-14.1pp	-3.3%-5.6pp	-0.8%+0.6pp
Current Ratio	31.18+25.7x	21.28+16.0x	22.23+13.3x	24.69+12.2x	5.45-11.4x	5.27-15.4x	8.93-5.2x	12.49-3.7x
Debt-to-Equity	1.16	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Liabilities-to-Equity	1.26+1.1x	0.54+0.4x	0.53+0.4x	0.55+0.4x	0.150.0x	0.140.0x	0.130.0x	0.140.0x
Asset Turnover	0.030.0x	0.030.0x	0.040.0x	0.080.0x	0.050.0x	0.050.0x	0.050.0x	0.050.0x
FCF Margin	37.7%+4.9pp	93.7%+150.3pp	76.9%+12.1pp	11.3%-58.0pp	32.7%+1.6pp	-56.6%-116.7pp	64.8%+37.6pp	69.3%+47.6pp

Not reported in any period shown, so not listed: Gross Margin.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Net Margin.

Where LIGAND PHARMS GLUCAGON Ranks

Frequently Asked Questions

What is LIGAND PHARMS GLUCAGON's annual revenue?

LIGAND PHARMS GLUCAGON (LGNXZ) reported $268.1M in total revenue for fiscal year 2025. This represents a 60.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is LIGAND PHARMS GLUCAGON's revenue growing?

LIGAND PHARMS GLUCAGON (LGNXZ) revenue grew by 60.4% year-over-year, from $167.1M to $268.1M in fiscal year 2025.

Is LIGAND PHARMS GLUCAGON profitable?

Yes, LIGAND PHARMS GLUCAGON (LGNXZ) reported a net income of $197.2M over the trailing 12 months to June 30, 2026. In fiscal year 2025 it reported a net income of $124.5M, with a net profit margin of 46.4%.

What is LIGAND PHARMS GLUCAGON's EBITDA?

LIGAND PHARMS GLUCAGON (LGNXZ) had EBITDA of $74.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is LIGAND PHARMS GLUCAGON's operating margin?

LIGAND PHARMS GLUCAGON (LGNXZ) had an operating margin of 15.3% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is LIGAND PHARMS GLUCAGON's net profit margin?

LIGAND PHARMS GLUCAGON (LGNXZ) had a net profit margin of 46.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is LIGAND PHARMS GLUCAGON's return on equity (ROE)?

LIGAND PHARMS GLUCAGON (LGNXZ) has a return on equity of 12.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is LIGAND PHARMS GLUCAGON's free cash flow?

LIGAND PHARMS GLUCAGON (LGNXZ) generated $48.9M in free cash flow during fiscal year 2025. This represents a -48.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is LIGAND PHARMS GLUCAGON's operating cash flow?

LIGAND PHARMS GLUCAGON (LGNXZ) generated $49.4M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are LIGAND PHARMS GLUCAGON's total assets?

LIGAND PHARMS GLUCAGON (LGNXZ) had $1.6B in total assets as of fiscal year 2025, including both current and long-term assets.

What are LIGAND PHARMS GLUCAGON's capital expenditures?

LIGAND PHARMS GLUCAGON (LGNXZ) invested $452K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does LIGAND PHARMS GLUCAGON spend on research and development?

LIGAND PHARMS GLUCAGON (LGNXZ) invested $81.2M in research and development during fiscal year 2025.

Does LIGAND PHARMS GLUCAGON buy back shares?

Yes, LIGAND PHARMS GLUCAGON (LGNXZ) spent $15.0M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does LIGAND PHARMS GLUCAGON have outstanding?

LIGAND PHARMS GLUCAGON (LGNXZ) had 20M shares outstanding as of fiscal year 2025.

What is LIGAND PHARMS GLUCAGON's current ratio?

LIGAND PHARMS GLUCAGON (LGNXZ) had a current ratio of 22.23 as of fiscal year 2025, which is generally considered healthy.

What is LIGAND PHARMS GLUCAGON's liabilities-to-equity ratio?

LIGAND PHARMS GLUCAGON (LGNXZ) had a liabilities-to-equity ratio of 0.53 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.

What is LIGAND PHARMS GLUCAGON's return on assets (ROA)?

LIGAND PHARMS GLUCAGON (LGNXZ) had a return on assets of 8.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is LIGAND PHARMS GLUCAGON's Piotroski F-Score?

LIGAND PHARMS GLUCAGON (LGNXZ) has a Piotroski F-Score of 4 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are LIGAND PHARMS GLUCAGON's earnings high quality?

LIGAND PHARMS GLUCAGON (LGNXZ) has an earnings quality ratio of 0.40x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can LIGAND PHARMS GLUCAGON cover its interest payments?

LIGAND PHARMS GLUCAGON (LGNXZ) has an interest coverage ratio of 8.70x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.